Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases

Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.

Year Invested: 2011
Location: Cambridge, Mass.

Recent News

May 2, 2018
Blueprint Medicines Reports First Quarter 2018 Financial Results

April 25, 2018
Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018

April 15, 2018
Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors

Read More News

Associated Team Members

Alexis Borisy